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Purpose: We aimed to investigate the significance of early detection of transition zone 
prostate cancer by transurethral resection of prostate (TURP) in benign prostatic hy-
perplasia (BPH) patients with lower urinary tract symptoms (LUTS) in whom prostate 
cancer was suspected despite a negative transrectal ultrasonography (TRUS) biopsy 
result.
Materials and Methods: From January 2006 to January 2009, a total of 165 patients 
who underwent TURP were evaluated. The prostate cancer detection rate was com-
pared between patients who underwent TRUS biopsy before TURP (group A) and those 
who did not (group B). All charts were evaluated retrospectively, including pros-
tate-specific antigen (PSA), digital rectal examination (DRE), TURP results (including 
resection volume and pathology report), TRUS, and TRUS biopsy results. Group A was 
subdivided into group A1, who were diagnosed with prostate cancer after TURP, and 
group A2, who were diagnosed with BPH after TURP.
Results: The cancer detection rate showed no significant difference between groups A 
and B (8.9% vs. 7.5%, p＞0.05). The mean PSA levels in groups A1 and A2 were 15.5±14.0
ng/ml and 9.1±5.1 ng/ml, respectively (p＞0.05). In group A1, 40% had an abnormal 
DRE, compared with 6.7% in group A2 (p＜0.05). After TURP, the mean percentage 
of resected prostatic chips of the prostate cancer group and BPH group were 33.9% and 
18.6%, respectively (p=0.001). A positive correlation was found between the detection 
rate of prostate cancer and PSA (p=0.01). 
Conclusions: BPH patients in whom prostate cancer is suspected and who have lower 
urinary tract symptoms (LUTS) with a previously negative TRUS biopsy result can un-
dergo TURP, which results in immediate improvement in bladder outlet obstruction 
and early diagnosis of clinically significant transition zone prostate cancer. 
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The incidence of prostate cancer is increasing in Korea ow-
ing to a westernization of dietary life. The detection rate 
of prostate cancer by transrectal ultrasonography (TRUS) 
biopsy has increased along with the utilization of both pros-
tate-specific antigen (PSA) and the digital rectal examina-
tion (DRE) as screening tests for prostate cancer. In the 
PSA era, the detection rate of stage T1c prostate cancer has 
increased. The diagnosis rate of T1a and T1b stage prostate 
cancer was 12.9% in the pre-PSA era in the late 1980s. 
However, upon the introduction of PSA, the diagnosis rate 
of stage T1a and T1b prostate cancer decreased to 8.0% in 
the late 1990s. It is noteworthy that there was no sig-
nificant difference in stage T1a prostate cancer, but there 
was a significant decrease in stage T1b prostate cancer [1]. 
　When TRUS biopsy is performed because of an elevated 
PSA value, the detection rate of prostate cancer can vary 
according to factors such as the location of the cancer in the 
prostate, the number of cores, and the method of TRUS 
biopsy. The detection rate of prostate cancer by TRUS biop-
sy by randomized sextant core has been reported to be 
25-30%; the detection rates of prostate cancer by sextant 
biopsy with meticulous focus on the far lateral portion and Korean J Urol 2010;51:313-317
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TABLE 1. Characteristics of the patients












Mean prostate volume (ml)
Mean TZ volume (ml)
TRUS hypoechoic lesion (%)
Abnormal DRE (%)
Mean PSA density (ng/ml/ml)





































Data presented as Mean±SD, IPSS: International Prostate Symptom Score, PSA: prostate-specific antigen, TZ: transition zone, TRUS: 
transrectal ultrasonography, DRE: digital rectal examination
that by 10-core and 12-core biopsy have been reported and 
advocated by many institutes [2,3]. With an increased 
number of biopsy cores, morbidity such as rectal bleeding, 
hematuria, fever, and pain does not increase significantly 
and unnecessary repeat biopsy is decreased [3]. Even with 
a negative result on an initial TRUS biopsy, repetition of 
TRUS biopsy is recommended when clinical suspicion of 
prostate cancer exists, such as with PSA elevation or an ab-
normal DRE [4]. However, it is difficult to detect prostate 
cancer by repeat TRUS biopsy when the tumor is located 
in the transition zone. Thus, transurethral biopsy or tran-
surethral resection of prostate (TURP) are the preferred 
approach in selected cases [4]. Transition zone prostate 
cancer is detected mostly on the anterior part of the pros-
tate and is hard to reach by TRUS biopsy [5]. The aim of 
this study was to evaluate the significance of early de-
tection of transition zone prostate cancer by TURP in be-
nign prostatic hyperplasia (BPH) patients with lower uri-
nary tract symptoms (LUTS) in whom prostate cancer was 
suspected despite a negative TRUS biopsy result.
MATERIALS AND METHODS
From January 2006 to January 2009, a total of 165 BPH 
patients with LUTS who underwent TURP were studied. 
TRUS biopsy was performed in those patients whose PSA 
was over 4 ng/ml or who had an abnormal nodule on the 
DRE. Patients with histologically confirmed prostate can-
cer by TRUS biopsy were excluded from this study. Regard-
less of TRUS biopsy, patients who had bladder outlet ob-
struction with LUTS underwent TURP to improve their 
LUTS, and TURP was performed 1 month after TRUS 
biopsy. The 12-core TRUS biopsy (including a 2-core tran-
sition zone biopsy) protocol was performed, and additional 
cores were sampled at hypoechoic lesions observed on the 
TRUS image. All patients’ charts were evaluated retro-
spectively, including International Prostate Symptom 
Score (IPSS), PSA, DRE, TURP results (including re-
section volume and pathology report), TRUS, and TRUS bi-
opsy results. 
　Patients who underwent TRUS biopsy were classified in-
to group A, and those who did not undergo TRUS biopsy 
were classified into group B. The detection rate of prostate 
cancer was compared bewteen the two groups. Group A was 
subdivided into group A1, who were diagnosed with pros-
tate cancer after TURP, and group A2, who were diagnosed 
with nodular hyperplasia after TURP. 
　IPSS/quality of life (QoL), PSA, DRE, TRUS, prostate 
volume, transition zone volume, and PSA density were 
compared between group A1 and group A2. Patients in 
group A were classified and compared by age (≤65 years, 
66-75 years, ≥75 years), DRE, and PSA (≤4 ng/ml, 4-10 
ng/ml, ≥10 ng/ml). The clinical stage and Gleason’s scores 
of patients who had diagnosed prostate cancer after TURP 
were analyzed. Statistical analysis was performed by exact 
chi-square test, Fisher’s exact test, and linear-by-linear as-
sociation with SPSS 13.0, and p-values of less than 0.05 
were deemed significant.
RESULTS
Prostate cancer was detected in 13 patients (7.9%), 8 of 
whom were diagnosed with stage T1a (4.8%) and 5 of whom 
were diagnosed with stage T1b (3%). Group A consisted of 
65 patients who had undergone TRUS biopsy before TURP, 
and 5 of those patients (7.7%) were diagnosed with prostate 
cancer. Among group B, 8 patients were diagnosed with 
prostate cancer (8.0%) (Table 1).
　In group A, the mean ages of group A1 and group A2 were 
72.6±5.7 years (median: 70 [range, 66-80]) and 70.1±7.3 
years, respectively. There was no significant difference in 
age between the two groups (p=0.458) (Table 1). The IPSS 
of group A1 and group A2 were 22.2±8.0 (median: 24 [range, 
11-32]) and 21.9±7.0, respectively (p=0.092) (Table 1). The 
mean PSA of group A1 (15.5±14.0 ng/ml; median: 7.3 
[range, 3.1-32.4]) was higher than that of group A2 (9.1±5.1 
ng/ml), but there was no significant difference between the 
two groups (p=0.368) (Table 1). The mean volume of the to-Korean J Urol 2010;51:313-317
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≤65 18 0 0
66-75 32 3  9.4
＞75 15 2 13.3
DRE 
Negative 59 3  5.1
Positive 6 2 33.3
PSA (ng/ml)
＜48 0 0
4-10 34 2  5.9
＞10 23 3 13
Data presented as Mean±SD, DRE: digital rectal examination, 
PSA: prostate-specific antigen
TABLE 3. Comparison between prostate cancer patients who 
underwent prostate biopsy and those who did not
Cancer (n=13)
Biopsy (n=5) Non biopsy (n=8)
Pathologic stage
T1a 3 5 
T1b 2  3 
Gleason score
6 3 4 
7 2  1
8 - 1 
9 - 2 
tal prostate was 58.9±20.7 ml (median: 62.6 [range, 
34.7-88.8 ml]) in group A1 and 69.1±32.4 ml in group A2 
(p=0.493) (Table 1). The mean volume of the transition zone 
was 30.5± 19.0 ml (median: 23.3 [range, 8.0-55.5 ml]) in 
group A1 and 31.3± 17.5 ml in group A2 (p=0.750) (Table 
1). There was a significant difference in the detection rate 
of hypoechoic lesions by TRUS between group A1, for which 
the rate was 100% (p=0.01) (Table 1), and group A2, for 
which the rate was 36.7%. A total of 40% of the patients in 
group A1 showed abnormal nodules on the DRE, whereas 
6.7% of patients in group A2 showed abnormal nodules on 
the DRE (p=0.063) (Table 1). Mean PSA density was 0.27± 
0.19 ng/ml/ml in group A1 (median: 0.16 [range, 0.03-0.52 
ng/ml/ml]) and 0.14±0.02 ng/ml/ml in group A2 (p=0.237) 
(Table 1). Mean PSA density by transition zone was 0.63± 
0.43 ng/ml/ml in group A1 (median: 0.67 [range, 0.06-1.32 
ng/ml/ml]) and 0.30±0.04 ng/ml/ml in group A2 (p=0.211) 
(Table 1). After TURP, the mean percentages of resected 
prostatic chips of the prostate cancer group and the BPH 
group were 33.9% and 18.6%, respectively (p=0.001).The 
detection rate of prostate cancer showed no significant dif-
ference with age (p=0.351, linear-by-linear association= 
0.198) (Table 2) or DRE (p=0.063) (Table 2). A positive cor-
relation was found between the detection rate of prostate 
cancer and PSA (p=0.01) (Table 2).
　Among 13 patients who were diagnosed with prostate 
cancer after TURP, 5 patients underwent TRUS biopsy be-
fore TURP, and the remaining patients did not undergo 
TRUS biopsy (Table 3).
　On the basis of clinical staging, of 5 patients who had un-
dergone TRUS biopsy before TURP, 3 patients (4.6%) were 
classified as having stage T1a cancer and 2 patients (3.1%) 
as having stage T1b. Of 8 patients who had not undergone 
TRUS biopsy before TURP, 5 patients (5.0%) were classi-
fied as having stage T1a cancer and 3 patients (3.0%) as 
having stage T1b (p=1.000) (Table 3).
　On the basis of Gleason’s score, among the patients who 
had undergone TRUS biopsy before TURP, 3 patients 
(60%) were classified as having a Gleason’s score of 6 and 
2 patients (40%) as having a Gleason’s score of 7. Among 
those who had not undergone TRUS biopsy before TURP, 
4 patients (50%) were classified as having a Gleason’s score 
of 6, 1 patient (12.5%) as having a Gleason’s score of 7, 1 
patient (12.5%) as having a Gleason’s score of 8, and 2 pa-
tients (25%) as having a Gleason’s score of 9 (p=0.641) 
(Table 3).
　Patients without TRUS biopsy before TURP showed 
higher Gleason’s scores, and clinically high-grade 
Gleason’s scores, including Gleason’s scores over 7, were 
detected in several cases, but there was no statistically sig-
nificant difference between the two groups. The patients 
who were diagnosed with prostate cancer after TURP were 
treated by active surveillance.
DISCUSSION
Despite the recent introduction of several minimally in-
vasive surgical methods of treating BPH, TURP has been 
recognized as the gold standard in the treatment of BPH. 
TURP is safe and feasible even in a large prostate, and it 
can replace open prostatectomy [6]. Bipolar TURP has been 
proven to be a safe and effective treatment alternative [7,8], 
leading to frequent application of TURP, even in large 
prostates. To the best of our knowledge, however, the de-
tection rate of prostate cancer after TURP has rarely been 
addressed in published reports [9].
　A diagnosis of stage T1a and T1b prostate cancer is made 
through pathologic examination of resected prostatic tis-
sue specimens from TURP. Otherwise, pathologic stages 
of T0, T2, or over T2 can be proved only after total excision 
of the prostate. The detection rate of stage T1a and T1b 
prostate cancer has been decreasing, mostly for the follow-
ing reasons. First, TURP has largely been replaced by phar-
macologic medication. Second, PSA is generally used as a 
screening test in patients with LUTS. Therefore, patients 
who should have been diagnosed with stage T1a-T1b are 
now diagnosed with stage T1c prostate cancer instead. 
Tombal et al reported that among patients who had under-Korean J Urol 2010;51:313-317
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gone surgical intervention, the rate of T1a prostate cancer 
decreased from 23% to 7% and that of T1b prostate cancer 
decreased from 15% to 2% between 1985 and 1997 [10,11]. 
Mai et al also reported that the proportion of stage T1a and 
T1b prostate cancer was 12.9% between 1989 and 1990, but 
that it decreased to 8.0% between 1997 and 1999 [1]. In our 
study, 13 patients (7.9%) were diagnosed with prostate 
cancer after TURP among the total 165 patients. Patients 
with T1a and T1b cancer numbered 8 (4.8%) and 5 (3.0%), 
respectively. Our results were similar to previously re-
ported data [1]. 
　In cases clinically suspicious of prostate cancer, TRUS 
biopsy is usually recommended. Recently, compared with 
sextant biopsy, extended biopsy such as 8-core biopsy, 
12-core biopsy, and more laterally oriented biopsy has been 
reported to provide an increased detection rate of prostate 
cancer [12].
　In cases of persistently high PSA, the detection rate of 
prostate cancer can rise from 77% in the first TRUS biopsy 
to 99% in the fourth biopsy with repeated TRUS biopsy [13]. 
However, TRUS biopsy is an invasive procedure that can 
cause complications such as infection, hemorrhage, and 
sepsis. Roehl et al reported a significant decrease in the 
prostate cancer detection rate to 10% if the results of the 
initial two TRUS biopsies are concluded to be negative [14]. 
Several reports have suggested the necessity of TURP to 
diagnose transition zone prostate cancer in patients with 
persistent elevation of PSA and repetitive negative TRUS 
biopsy results. Puppo et al reported that performing TURP 
and lateralized TRUS biopsy in patients with 3 or more pre-
vious negative TRUS biopsies can raise the detection rate 
up to 57% [6]. Recently, repetitive negative prostate cancer 
results were evaluated with extended biopsy and TURP. 
In cases with a history of 2 or more negative TRUS biopsies, 
extended saturation biopsy and concomitant TURP showed 
a reasonable diagnostic yield and relief of obstruction [15]. 
The use of TURP as a diagnostic tool was founded by the 
fact that most transition zone prostate cancer is located at 
the anterior part of the prostate, which is difficult to ap-
proach by TRUS biopsy [5]. Steuber et al reported the differ-
ent biological characteristics of transition zone cancer, 
which shows a lower grade; additionally, in radical prosta-
tectomy specimens, satellite tumors were noted with high-
er grades in the peripheral zone [16]. In our study, 2 tran-
sition zone biopsy cores were included in the TRUS biopsy 
protocol. In cases of BPH, especially in prostates of over 50 
g, the peripheral zone is compressed and thinned by hyper-
plasia of the transition zone. Therefore, biopsy cores that 
target the medial peripheral zone can include the tran-
sition zone as well as the peripheral zone, thus lowering the 
necessity for additional transition zone biopsies [17]. 
Therefore, in cases of BPH patients who complain of severe 
LUTS and with a clinical suspicion of prostate cancer after 
negative results of a 12-core TRUS biopsy with no high- 
grade prostatic intraepithelial neoplasia (PIN), atypical 
small acinar proliferation (ASAP), or persistent elevation 
of PSA, immediate TURP is a reasonable approach owing 
to the rapid relief of bladder outlet obstruction and feasible 
diagnosis of transition zone prostate cancer.  
　Concerning the treatment of prostate cancer after TURP, 
Puppo et al reported that previous TURP had no negative 
effects on the outcomes of radical prostatectomy. In a pre-
vious study, radical prostatectomy after TURP was re-
ported to be more difficult because of worsened conditions 
for radical retropubic prostatectomy (RRP), such as peri-
prostatic fibrotic tissue, bladder neck injury, and capsular 
violation [18]. However, in recent reports, perioperative 
morbidity and functional results, such as continence and 
erectile function, in open RRP after TURP were com-
parable with those after RRP alone with no previous TURP 
[19]. Recently, laparoscopic radical prostatectomy has 
been performed after TURP. Although it is a challenging 
procedure owing to the distortion of the surgical planes, it 
was oncologically safe and overall potency rates were pre-
served [20]. 
　In our study, there was no significant difference in the 
detection rate of prostate cancer between the prostate can-
cer suspicious group (8.9%) and the nonsuspicious group 
(7.5%). Our pathologic results showed 1 patient (12.5%) 
who had a Gleason’s score of 8 and 2 patients (25%) who had 
a Gleason’s score of 9. These results suggest that a rela-
tively high rate of clinically significant tumors were de-
tected by TURP, and prostate cancer that was detected by 
TURP could be treated surgically, such as by RRP or laparo-
scopic radical prostatectomy in selective cases.  
　Kitamura et al suggested that TURP should be per-
formed only in patients who complain of LUTS, because 
most clinically nonsignificant prostate cancer is diagnosed 
by performing concomitant sextant biopsy and transition 
zone biopsy [21]. However, van Renterghem et al reported 
improvement of bladder outlet obstruction, normalization 
of PSA, and diagnosis of clinically significant prostate can-
cer by performing TURP [22].
　In our study, the proportion of stage T1a and of stage T1b 
prostate cancer was not significantly different between 
groups A and B. These data can lead to the conclusion that 
TURP does not significantly influence clinical staging in 
T1a, T1b transition zone prostate cancer. Thus, performing 
TURP in patients with previously negative TRUS biopsy 
results who are clinically suspicious for prostate cancer 
would not significantly influence the treatment of prostate 
cancer. Furthermore, most transition zone prostate cancer 
was located at the anterior part of the prostate, which is 
difficult to approach by TRUS biopsy. Approach to the tran-
sition zone is better by TURP, which could relieve bladder 
outlet obstruction and detect transition zone prostate cancer.
CONCLUSIONS
The clinical stage of T1a, T1b prostate cancer was similar 
between the prostate cancer suspicious BPH group and the 
nonsuspicious group. Also, even with 12-core TRUS biopsy, 
which included 2-core biopsy of the transition zone, precise 
access to the transition zone is troublesome. Therefore, Korean J Urol 2010;51:313-317
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BPH patients with a clinical suspicion of prostate cancer 
who have LUTS and a previously negative TRUS biopsy re-
sult can undergo TURP, which results in immediate im-
provement of the bladder outlet obstruction and early diag-
nosis of clinically significant transition zone prostate 
cancer. 
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